Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262963 · ClinicalTrials.gov registry record · Phase 1
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01262963 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4 participants.
The verdict
NCT01262963, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study is a Phase 1, open-label study designed to characterize the absorption, distribution, metabolism and excretion of GSK2118436 following administration of a single oral 14C labeled dose of GSK2118436 as a suspension in subjects with BRAF mutation positive tumors.
Interventions
- DRUG GSK2118436
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01-26 |
| Est. Completion | 2011-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262963
The ClinicalTrials.gov registry entry for NCT01262963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2118436 is the first listed.
NCT01262963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262963 about?
NCT01262963 is a clinical study titled "An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors". The study is a Phase 1, open-label study designed to characterize the absorption, distribution, metabolism and excretion of GSK2118436 following administration of a single oral 14C labeled dose of GSK2118436 as a suspension in subjects with BRAF mutation positive tumors.
What is the current status of trial NCT01262963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-01-26. Estimated completion is 2011-04-08.
What interventions are being tested in trial NCT01262963?
The interventions under investigation include: GSK2118436 (DRUG).
Who is sponsoring clinical trial NCT01262963?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.